RF A089
Alternative Names: RF-A089Latest Information Update: 28 Oct 2021
At a glance
- Originator Hubei Biological Medicine Industrial Technology Institute
- Class Antineoplastics
- Mechanism of Action Anaplastic lymphoma kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-small cell lung cancer
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO, Capsule)
- 13 Sep 2018 Phase-I clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO) (ChiCTR1800018660)